The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Esperion Theraptc has an asset utilization ratio of 24.59 percent. This connotes that the company is making $0.25 for each dollar of assets. An increasing asset utilization means that Esperion Theraptc is more efficient with each dollar of assets it utilizes for everyday operations.
What is the right price you would pay to acquire a share of Esperion Therapeutics? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the
future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our
stock advisor page.
What is happening with Esperion Therapeutics this year
Annual and quarterly reports issued by Esperion Therapeutics are formal
financial statements that are published yearly and quarterly and sent to Esperion stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the
Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Esperion Therapeutics often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
Going after Esperion Financials
Earning per share calculations of Esperion Theraptc is based on official Zacks consensus of 5 analysts regarding Esperion Theraptc's future annual earnings. Given the historical accuracy of 82.55%, the future earnings per share of the company is estimated to be -9.68 with the lowest and highest values of -10.85 and -7.74, respectively. Please note that this consensus of annual earnings estimates for the firm is an estimate of EPS before non-recurring items and including employee stock options expenses.
Is Esperion a risky opportunity?
Let's check the volatility. Esperion is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Esperion (NASDAQ:ESPR) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. buying a share of an Esperion Theraptc stock makes you a part-owner of that company.
Esperion Theraptc Current Consensus
Here is the latest trade recommendation based on an ongoing consensus estimate among financial analysis covering Esperion Theraptc. The Esperion consensus assessment is calculated by taking the average estimates from all of the analysts covering Esperion Theraptc
| Strong Buy2 | Buy1 | Hold3 | Strong Sell2 |
| Strong Buy | 2 | 25.0 |
| Buy | 1 | 12.5 |
| Hold | 3 | 37.5 |
| Sell | 0 | 0.0 |
| Strong Sell | 2 | 25.0 |
Our take on today Esperion Theraptc spike
The downside variance is down to 20.67 as of today. Esperion Theraptc shows above-average downside volatility for the selected time horizon. We advise investors to inspect Esperion Theraptc further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Esperion Theraptc future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Esperion Theraptc's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Esperion Theraptc's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Esperion Theraptc Implied Volatility
Esperion Theraptc's implied volatility exposes the market's sentiment of Esperion Theraptc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Esperion Theraptc's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Esperion Theraptc stock will not fluctuate a lot when Esperion Theraptc's options are near their expiration.
Our Final Take On Esperion Theraptc
While some other companies within the drug manufacturers—specialty & generic industry are still a little expensive, even after the recent corrections, Esperion Theraptc may offer a potential longer-term growth to retail investors. All things considered, as of the 3rd of May 2022, our concluding 90 days 'Buy-Sell' recommendation on the enterprise is
Strong Hold. We believe Esperion Theraptc is
undervalued with
quite high probability of bankruptcy for the next two years.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Esperion Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
